An independent COVID-19 Therapeutics Advisory Panel (UK-CTAP), chaired by Professor Patrick Chinnery, will advise on what treatments should be proposed for testing through RECOVERY+, REMAP-CAP, PRINCIPLE and AGILE. The panel is formed by a group of experts with no vested interests from relevant backgrounds who have broad expertise covering key issues. The panel will take specialist advice from sub-panels with expertise in strategically important areas for the treatment of COVID-19. These areas will change as we learn more about disease mechanisms in COVID-19 and its complications, and we advance our knowledge of the most effective treatments. The final decision on which treatments will be included in in these trials will lie with the Chief Investigators, who have ultimate responsibility for the delivery of the trials and Professor Chris Whitty, the Chief Medical Officer for England and Chief Scientific Adviser for the Department of Health and Social Care. The UK-CTAP will be supported by a UK Research and Innovation (UKRI) led secretariat. The membership of the group and the record of the meetings will be published and updated periodically to reflect any changes in the membership details and the drug prioritisation process.